| CAS NO: | 891494-63-6 |
| 包装 | 价格(元) |
| 10 mM * 1 mL in DMSO | 电议 |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| 500mg | 电议 |
| 生物活性 | SCH900776 (MK-8776) is a potent, selective and orally bioavailable inhibitor of checkpoint kinase1 (Chk1) with anIC50of 3 nM. SCH900776 shows 50- and 500-fold selectivity overCDK2andChk2, respectively[1][2]. | ||||||||||||||||
| IC50& Target[2] |
| ||||||||||||||||
| 体外研究 (In Vitro) | SCH900776 (300 nM) shows potent inhibitory activities against phosphorylation at ser296-Chk1. SCH900776 (1 μM) causes a 30-fold decrease in the IC50for NSC-32065 in MDA-MB-231 cells[1]. The Kdvalue of SCH 900776 for the CHK1 kinase domain is 2 nM. SCH 900776 exhibits an approximate EC50of 60 nM in cells exposure to NSC-32065. SCH 900776 induces dose-dependent suppression of CHK1 pS296 and concomitant accumulation of phospho-RPA signal in U2OS cells[2]. | ||||||||||||||||
| 体内研究 (In Vivo) | SCH 900776 induces the γ-H2AX biomarker at 4 mg/kg (i.p.), and enhances tumor pharmacodynamic and regression responses in A2780 xenograft model. SCH 900776 (16 and 32 mg/kg, i.p.) induces incremental improvements in tumor response. Escalation of SCH 900776 dose to 20 and 50 mg/kg in combination with LY 188011 results in improvements in TTP 10× in the A2780 xenograft systems[2]. | ||||||||||||||||
| Clinical Trial | |||||||||||||||||
| 分子量 | 376.25 | ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| Formula | C15H18BrN7 | ||||||||||||||||
| CAS 号 | 891494-63-6 | ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
| 储存方式 |
| ||||||||||||||||
| 溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(265.78 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
